Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- VeroVero Combines Stanford's Proteomic Organ and Cell Aging Technologies to Build a New Clinical and Consumer Tool for Predictive HealthCORTE MADERA, Calif., August 18, 2026--Vero, a predictive health company on a mission to end age-related chronic disease, today announced it is adding cellular resolution to its OrganAge™ platform with an exclusive consumer license to Stanford’s proteomic Cell Clock technology. Developed in the laboratory of Vero co-founder Dr. Tony Wyss-Coray, Cell Clocks measure biological aging across specific cell types, providing a deeper view into the drivers of organ aging and disease risk.
- The National Association for Continuing EducationThe National Association for Continuing Education (NACE) Announces Reaccreditation by the Accreditation Council for Continuing Medical Education (ACCME)NEW YORK, August 18, 2026--The National Association for Continuing Education (NACE) is pleased to announce that it has been reaccredited as a provider of continuing education by the Accreditation Council for Continuing Medical Education (ACCME), from July 2026 - July 2030. NACE has received a four-year accreditation as a provider of continuing education for the health professions, having achieved compliance with all core criteria for accreditation.
- Global Health Insurance Market Growth and Strategy Outlook 2026-2031 | Employer-Sponsored Health Insurance Remains a Major Market DriverThe "Health Insurance - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
- Crescendo HealthCrescendo Health Appoints David Strutton, PhD as Chief Scientific OfficerSAN FRANCISCO, August 18, 2026--Crescendo Health, a leader in modernizing clinical research data infrastructure, today announced the appointment of David Strutton, PhD, as Chief Scientific Officer (CSO). In this role, Dr. Strutton will lead the company’s scientific strategy, evidence generation frameworks, and customer solutions to advance patient-centric clinical research.
- Consano BioConsano Bio Receives FDA Fast Track Designation for C-1101 in Chronic, Painful Lumbosacral Radiculopathy (LSR) or Chronic SciaticaDesignation follows recent FDA clearance of the Company's IND application for C-1101, an investigational, potentially disease-modifying non-opioid biologic — Consano Bio, Inc., a clinical-stage biotechnology company advancing novel...
- Sitero, LLCSitero Extends Ash, a Clinical AI Agent, Across the Full Clinical Data LifecycleSitero today released three Ash agentic workflows simultaneously, covering clinical study setup, continuous data review, and portfolio-level insights, all governed by human review at every step. — Sitero, a clinical research organization...
- Humacyte, Inc – Jeromy BrinkBoard-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved bioengineered human blood vessel –
- EphicacyEphicacy Appoints Dr. Shekhar Thumake as Head of AI to Advance AI-Enabled Clinical Data OperationsISELIN, N.J, August 18, 2026--Ephicacy today announced the appointment of Dr. Shekhar Thumake as head of AI, a new role that reflects the company’s growing investment in artificial intelligence across its biometrics operations.
- Stuart Therapeutics, Inc.Stuart Therapeutics, Inc. Appoints David Jakeman as Chief Financial OfficerSTUART, Fla., August 18, 2026--Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company developing first-in-class collagen-reparative therapeutics to treat eye diseases, today announced the appointment of David Jakeman as chief financial officer. Jakeman will lead the company's finance and accounting operations as Stuart advances its lead candidate, ST-100 for dry eye disease, through completion of its pending Phase 3b clinical trial and into preparations for commercializ
- Dunbar PharmaceuticalsDunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS PharmaATHLONE, Ireland, August 18, 2026--Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma
- LEO PharmaLEO Pharma Further Strengthens Late-Stage Pipeline With the Acquisition of DersimelagonBALLERUP, Denmark, August 18, 2026--LEO Pharma, a global leader in medical dermatology delivering innovative solutions for skin disease, today announces that it has entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma. Dersimelagon is an oral, once-daily small MC1R agonist being developed for EPP and XLP.
- Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in AustraliaHansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication...